Skip to main content
. 2022 Dec 8;6(2):e202201533. doi: 10.26508/lsa.202201533

Figure 4. Anti-CD3/SLAMF6–bispecific antibody clusters SLAMF6 to the CD3 and augments T cell activation.

Figure 4.

(A) A schematic representation of anti-CD3/SLAMF6–bispecific antibody (aCD3/SLAMF6) binding and clustering the two receptors together. (B) aCD3/SLAMF6 antibody binding was validated using an ELISA assay: αCD3 binding was assessed against immobilized SLAMF6 KO Jurkat T cells, whereas anti-SLAMF6 binding was assessed against immobilized Raji B cells. (C) Jurkat T cells were treated with αCD3, αCD3 + soluble αSLAMF6, or aCD3/SLAMF6 at three different concentrations of the bispecific antibody: 0.1, 1, and 10 µg/ml. After 24 h, IL-2 levels were analyzed by ELISA for at least two independent experiments (n = 2). (D) Raji B cells were preloaded with increasing concentrations of SEE and co-cultured with Jurkat T cells in the absence (blue) or presence (magenta) of 1 µg/ml of aCD3/SLAMF6 antibody. IL-2 levels were analyzed for at least two independent experiments (n = 2). (E) Raji B cells were preloaded with SEE and co-cultured with Jurkat T cells at increasing concentrations of the αCD3/SLAMF6 antibody. IL-2 levels were analyzed for at least two independent experiments (n = 2). *P < 0.05, **P < 0.01, ***P < 0.001 for an unpaired t test.